Sector News

Kiss more pharma jobs goodbye: Pierre Fabre to cut 550 in sales, R&D

December 11, 2014
Life sciences
Pierre Fabre hasn’t had an easy time in the drug business lately. Its R&D operations have been less than productive, executives say, and sales in its home country have suffered from price cuts.
So, it’s scaling back in pharma to narrow its R&D focus, build up in consumer healthcare and spend more resources on its cosmetics and dermatology businesses. The upshot? Pierre Fabre will shrink its pharma payroll by 551 jobs by 2016. The cuts will mainly affect its French operations, with sales and R&D both in the target zone.
The larger cuts will come in R&D, which will lose 272 jobs, 255 in France, the company said in a statement. Another 279 or so will hit on the sales side. The rest will come from an R&D site in Barcelona that’s slated for closure.
The job cuts aren’t likely to be popular in France, where Sanofi ran into trouble with its own restructuring. Nor are the company’s comments about its R&D operations in the country, which it called “insufficiently productive.” That, too, echoes Sanofi, whose now-former CEO Chris Viehbacher cited the same reason for his French job-cutting plans in R&D.
Pierre Fabre is far from the only drugmaker cutting jobs and paring away lackluster businesses–not to mention scaling back in France. Novartis just cut 200 people from its New Jersey payroll in a sales-force shift, and it’s cutting other jobs around the world as it consolidates back-office operations. The Swiss drugmaker is also in the midst of a wholesale strategic shift, selling its animal health business to Eli Lilly and swapping its vaccine business to GlaxoSmithKline for GSK’s oncology operations. GSK announced job cuts last week as well.
Bristol-Myers Squibb also said last week it would hack 1,000 from its Chinese payroll. And Merck is cutting costs–as well as jobs–as it narrows its focus; the U.S.-based drugmaker recently sold its consumer business to Bayer.
By Tracy Staton

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]